A detailed history of Shell Asset Management CO transactions in Vir Biotechnology, Inc. stock. As of the latest transaction made, Shell Asset Management CO holds 5,045 shares of VIR stock, worth $37,232. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,045
Previous 4,896 3.04%
Holding current value
$37,232
Previous $44,000 13.64%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$7.26 - $10.7 $1,081 - $1,594
149 Added 3.04%
5,045 $38,000
Q1 2024

Jul 31, 2024

SELL
$8.6 - $11.9 $2,614 - $3,617
-304 Reduced 5.85%
4,896 $44,000
Q1 2024

May 14, 2024

SELL
$8.6 - $11.9 $3,053 - $4,224
-355 Reduced 6.39%
5,200 $53,000
Q4 2023

Feb 14, 2024

SELL
$7.76 - $10.29 $13,005 - $17,246
-1,676 Reduced 23.18%
5,555 $56,000
Q3 2023

Nov 08, 2023

SELL
$9.14 - $24.62 $1,032 - $2,782
-113 Reduced 1.54%
7,231 $68,000
Q2 2023

Jul 28, 2023

SELL
$23.2 - $27.29 $974 - $1,146
-42 Reduced 0.57%
7,344 $180,000
Q1 2023

May 15, 2023

SELL
$22.26 - $30.85 $578 - $802
-26 Reduced 0.35%
7,386 $172,000
Q4 2022

Feb 07, 2023

SELL
$19.96 - $28.22 $30,039 - $42,471
-1,505 Reduced 16.88%
7,412 $188,000
Q3 2022

Nov 14, 2022

SELL
$18.26 - $31.1 $42,655 - $72,649
-2,336 Reduced 20.76%
8,917 $172,000
Q2 2022

Aug 09, 2022

BUY
$19.08 - $26.7 $158,745 - $222,144
8,320 Added 283.67%
11,253 $287,000
Q1 2022

May 04, 2022

SELL
$21.19 - $40.01 $9,090 - $17,164
-429 Reduced 12.76%
2,933 $75,000
Q4 2021

Feb 09, 2022

BUY
$30.97 - $54.03 $805 - $1,404
26 Added 0.78%
3,362 $141,000
Q3 2021

Nov 04, 2021

SELL
$34.9 - $54.54 $4,188 - $6,544
-120 Reduced 3.47%
3,336 $145,000
Q2 2021

Aug 12, 2021

BUY
$38.75 - $51.0 $133,920 - $176,256
3,456 New
3,456 $163,000

Others Institutions Holding VIR

About Vir Biotechnology, Inc.


  • Ticker VIR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 132,638,000
  • Market Cap $979M
  • Description
  • Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...
More about VIR
Track This Portfolio

Track Shell Asset Management CO Portfolio

Follow Shell Asset Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Shell Asset Management CO with notifications on news.